Table 2 Demographic and clinicopathologic data between two groups

Age, years

66.4 ± 5.6

61.2 ± 4.2

0.231

Gender

0.614

 Male

29 (61.7)

138 (57.7)

 Female

18 (38.3)

101 (42.3)

ECOG score

<0.001

 ≤ 1

16 (34.0)

174 (72.8)

 ≥ 2

31 (66.0)

65 (27.2)

Tumor site

0.028

 Stomach

43 (91.5)

176 (73.6)

 Small intestine

3 (6.4)

48 (20.1)

 Others^a

1 (2.1)

15 (6.3)

Tumor size, cm

1.6 ± 0.4

5.9 ± 3.5

<0.001

 Median (range, cm)

0.7 (0.2~2.5)

5.25 (1.5~30.0)

Mitotic count (50 HPF)

0.011

 ≥ 10

0 (0.0)

27 (11.3)

 < 10

47 (100.0)

212 (88.7

NIH risk classification

<0.001

 Very low and low

42 (89.4)

76 (31.8)

 Intermediate and high

5 (10.6)

163 (68.2)

IM adjuvant treatment

<0.001

 Yes

2 (4.3)

139 (58.2)

 No

45 (95.7)

100 (41.8)

Synchronous cancer

 Esophageal carcinoma

12 (25.5)

–

 Gastric carcinoma

27 (57.4)

–

 Pancreatic adenocarcinoma

1 (2.1)

–

 Colorectal carcinoma

7 (14.9)

–

Hospital stay, days

18.6 ± 5.3

16.9 ± 4.2

0.209